Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Díaz-Guerra, M. J.M.
Right arrow Articles by Boscá, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Díaz-Guerra, M. J.M.
Right arrow Articles by Boscá, L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 47, Issue of November 22, 1996 pp. 30114-30120
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Evidence for Common Mechanisms in the Transcriptional Control of Type II Nitric Oxide Synthase in Isolated Hepatocytes
REQUIREMENT OF NF-kappa B ACTIVATION AFTER STIMULATION WITH BACTERIAL CELL WALL PRODUCTS AND PHORBOL ESTERS*

(Received for publication, January 24, 1996, and in revised form, August 6, 1996)

María J. M. Díaz-Guerra , Marta Velasco , Paloma Martín-Sanz and Lisardo Boscá Dagger

From the Instituto de Bioquímica (CSIC-UCM), Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

Incubation of primary cultures of rat hepatocytes with lipopolysaccharide (LPS), S-[2,3-bis(palmitoyloxy)-(2-R,S)-propyl]-N-palmitoyl-(R)-Cys-Ser-Lys4 (TPP), a synthetic lipopeptide present in bacterial cell wall lipoproteins, or with phorbol 12,13-dibutyrate (PDBu) induced an increase in nitric oxide synthesis through the expression of type II nitric oxide synthase (iNOS). Transfection of hepatocytes with a HindII fragment corresponding to the promoter region of the murine iNOS gene (from nucleotide -1588 to +165) resulted in the expression of the reporter gene when cells were stimulated with these factors. The transcription factors activated by these stimuli involved an increase in the nuclear content of proteins that bind to kappa B, AP-1, GAS, and SIE sequences. Inhibition of NF-kappa B activation with pyrrolidine dithiocarbamate eliminated the expression of iNOS in hepatocytes stimulated with LPS, TPP, or PDBu. In addition to this, transfection of hepatocytes with promoter mutants in which a sequential 2-base pair change within the kappa B sites was introduced (position -971 to -961 and -85 to -75, respectively), resulted in approximately 17 and 35%, respectively, of the activity of the naive promoter. Simultaneous mutation of both kappa B sites abolished the promoter activity. Analysis of the proteins involved in kappa B binding showed the presence of p50/p65 dimers in the nuclei of activated cells at the time that an important decrease of Ikappa B-alpha was observed soon after cell stimulation with LPS, TPP, or PDBu. However, only LPS was able to decrease the amount of Ikappa B-beta . These results suggest that LPS, TPP, and PDBu, although activating different signal transduction pathways, use a common mechanism mediating iNOS expression in cultured hepatocytes.


INTRODUCTION

The involvement of nitric oxide in different pathophysiological pathways is a subject of current research (1, 2). Three different nitric oxide synthase species have been identified in mammalian tissues, each exhibiting an important degree of tissue-specific expression as well as significant differences in their regulatory properties (1, 2, 3). The species recognized as type II nitric oxide synthase (iNOS)1 is induced in a number of different cell types in response to cytokines involved in inflammation and host defense as well as by bacterial cell wall products and some pharmacological agents (3, 4, 5, 6). The promoter region of iNOS has been characterized in different species, including humans and mice (7, 8). A 1753-base pair fragment of the promoter region of iNOS has been cloned and characterized from the murine RAW 246.7 macrophage cell line (8, 9, 10). Sequence analysis of this promoter revealed the presence of at least 24 consensus motifs for binding of transcription factors, including 2 copies for nuclear factor kappa B (NF-kappa B), 2 copies for activator protein-1 (AP-1), 10 copies of IFN-gamma response elements (gamma -IRE), 3 copies of the gamma -activated site (GAS), 2 copies of the IFN-stimulated response element (ISRE), and 2 copies of the tumor necrosis factor-alpha responsive element, among others (8, 9, 10, 11). Functional analysis in RAW 264.7 cells using deletional mutants of the iNOS promoter revealed the presence of two important regulatory regions, each one containing a kappa B binding site for NF-kappa B and exhibiting an important interaction of their roles in activation of iNOS transcription (8, 9). These regions cover 200 base pairs upstream of the start site of transcription and positions -913 to -1020 and have been referred to as the proximal and distal regulatory regions, respectively (8, 9). In addition to the cooperation between these two regions, a concerted synergism among nuclear factor binding sites exists in each region. This is the case for macrophages, where the interaction elicited by suboptimal concentrations of LPS and IFN-gamma on NO synthesis has been demonstrated to be the result of a cooperative interaction between the IFN regulatory factor 1 and NF-kappa B sites in the distal region (12, 13).

Apart from macrophages, iNOS is induced in a variety of other cell types such as neural cells, keratinocytes, myocytes, mesangial cells, tumor cells, and hepatocytes in response to a wide array of either physiological or pathological cellular stresses (1). In the case of the liver, both hepatocytes and Kupffer cells express iNOS in response to different cell stimuli such as septic shock, cirrhosis, hyperdynamic circulation, or after partial hepatectomy (14, 15, 16). Moreover, primary cultures of hepatocytes retain their ability to express iNOS after exposure to LPS, TPP, or after treatment with phorbol esters that are pharmacological activators of protein kinase C (5, 6). All of these molecules induce by themselves the expression of a functional iNOS as deduced by the large amounts of NO released to the medium (5, 6, 14, 15, 16). Hepatocytes also constitute an interesting experimental model because these cells have an extremely high transcriptional rate in combination with a very low proliferative capacity, and, therefore, most of the transcriptional factors required for commitment to cell growth are switched off (17). In this regard, we have investigated the factors involved in the transcriptional activation of hepatic iNOS in response to three defined effectors that, because of its unrelated chemical structure, act on the hepatocyte through different transduction pathways; LPS acts through the engagement of CD14 (18), whereas the TPP receptor remains elusive (6, 19). Phorbol esters are potent activators of protein kinase C subspecies containing a tandem of two zinc-finger domains and whose expression pattern varies between tissues (20). The ability of cells to express iNOS in response to phorbol esters appears to be restricted to some cell types, including rat hepatocytes and peritoneal macrophages (5, 21). For this reason we investigated the pattern of transcriptional factors relevant to iNOS expression in hepatocytes incubated with these three stimuli.

Our results show that treatment of primary cultures of hepatocytes with LPS, TPP, and phorbol esters trigger a similar pattern of transcription factor activation, including members of the NF-kappa B, AP-1, GAS, and SIE binding proteins. This transactivation was also evident in hepatocytes transfected with plasmids encoding the murine iNOS promoter or consensus sequences for the binding of NF-kappa B and AP-1 linked to a CAT reporter gene. These results suggest that the expression of iNOS in hepatocytes in response to LPS, TPP, and phorbol esters is mediated through the engagement of a similarly regulated transcriptional mechanism.


MATERIALS AND METHODS

Reagents

Cytokines and biochemicals were from Sigma. Materials and chemicals for electrophoresis were from Bio-Rad. S-[2,3-bis(palmitoyloxy)-(2-R,S)-propyl]-N-palmitoyl-(R)-Cys-Ser-Lys4 (TPP) was from Boehringer Mannheim. LPS was from Salmonella typhimurium. Plasmids were purified by extensive washing using Qiagen columns (Hilden, FRG). The endotoxin content in cytokines and plasmid preparations was determined using the Limulus polyphemus test (Sigma) and was below 0.1 ng/mg protein and 30 pg/ml plasmid dilution, respectively, at the dose used for transfection. Serum and media were from BioWhittaker (Walkersville, MD).

Isolation and Culture of Hepatocytes

Isolation of hepatocytes was carried out from 3-month-old male rats by perfusion with collagenase in Krebs-bicarbonate buffer under continuous gassing with carbogen (O2/CO2, 19:1) and following the classic recirculation protocol (5). The hepatocyte suspension was washed twice with sterile Dulbecco's modified Eagle's medium and then resuspended in this medium supplemented with 50 µg/ml gentamicin, 50 µg/ml penicillin G, and 50 µg/ml streptomycin (incubation medium). The hepatocytes (3 × 106) were plated in 6-cm tissue culture dishes in a medium containing 2.5 ml of Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. After 4 h of incubation to facilitate cell attachment to the matrix, the medium was aspirated, and the plates were washed twice with PBS to remove the nonadherent cells and filled with 2.5 ml of Dulbecco's modified Eagle's medium lacking serum. Additions were made so that the changes in the total incubation volume were less than 2%.

Transfection of Hepatocytes and CAT Assays

Freshly isolated hepatocytes were transfected by electroporation (22). Cells (4 × 106 in 0.8 ml of PBS) were kept at 4 °C and electroporated at 300 V, 960 µF in a BTX electroporator (Electrocell Manipulator 600) in the presence of 10 µg of plasmid. Electroporated cells were maintained for 10 min at 4 °C and then transferred to 6-cm dishes filled with 3 ml of Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics at 37 °C. After 6-8 h of culture, the medium was aspirated and the dishes washed twice with PBS to remove nonadhered cells. The hepatocytes were maintained overnight with incubation medium supplemented with 2% of heat-inactivated fetal calf serum. Twenty-four hours after electroporation the medium was replaced by fresh medium and the cells were stimulated with different factors. To determine CAT activity, the cells were incubated with the stimuli for 36 h. After two washes of the plates with ice-cold PBS, the cells were scraped off the dishes. After centrifugation, the cell pellets were resuspended in 100 µl of 100 mM potassium phosphate (pH 7.8) and 1 mM dithiothreitol and disrupted by three cycles of freezing and thawing followed by centrifugation at 12,000 × g for 10 min. The supernatant was heated at 65 °C for 10 min, and CAT activity was measured by synthesis of acetylated [14C]chloramphenicol following the TLC method (22, 23). CAT activity was expressed as the percentage of the activity measured in cells electroporated with a kSV2CAT plasmid (23). As an additional control to ensure that the plasmids were free of bacterial products involved in NO synthesis, electroporated cells in the absence of plasmids received an equivalent dose of plasmid upon culture.

Plasmids

The 1753-base pair HindII fragment corresponding to the 5'-flanking region of iNOS fused to a promoterless CAT reported gene (p1iNOS-CAT) (8) was a generous gift from Dr. Q.-w. Xie and Dr. C. Nathan. Plasmids (kappa B)3ConACAT, (AP-1)2ConACAT, and ConACAT have 3 copies of the kappa B motif from the human immunodeficiency virus long terminal repeat enhancer, two copies of the AP-1 motif from the collagenase promoter or the minimal promoter with no enhancer element of the conalbumin A promoter (used as a control), respectively, and have been previously described (24). Mutated kappa B promoter plasmids were generated by polymerase chain reaction using oligonucleotide primers in which 2 GG bases of the kappa B motif were substituted by a CC pair, kindly given by Dr. T. J. Evans (25). A scheme of these promoter mutants is shown in Fig. 9. Deletions of the p1iNOS vector were generated by digestion with EspI, SmaI, and SacI, respectively, which generated the plasmids p1NOS(Delta 1) (nucleotides -1029 to +165), p1NOS(Delta 2) (nucleotides -725 to +165), and p1NOS(Delta 3) (nucleotides -333 to +165), respectively (see Fig. 9). The vectors were sequenced to ascertain their fidelity. A kSV2CAT plasmid in which the CAT gene is driven by the simian virus 40 early promoter and enhancer as a control in transfection assays (22).


Fig. 9. Role of NF-kappa B and AP-1 on the activity of the iNOS promoter in stimulated hepatocytes. Primary cultures of hepatocytes were transfected with the indicated vectors. Cells were stimulated for 24 h with LPS (1 µg/ml), TPP (5 µg/ml), or PDBu (40 nM), and CAT activity was measured. The activity of the different promoters for each treatment was referred to the pNOS-kappa B vector taken as 100%. The activity of the pNOS-kappa B promoter was 17, 18, and 11% of the kSV2CAT vector in cells stimulated with LPS, TPP, and PDBu, respectively. The vectors containing mutated kappa B sites are indicated by the 2-base substitutions introduced in the GGG motif. Results show the mean ± S.E. of three experiments.
[View Larger Version of this Image (28K GIF file)]


Determination of NO

NO release was determined spectrophotometrically by the accumulation of nitrite and nitrate in the medium (phenol red-free) as follows: 250 µl of culture medium were transferred to 1.5-ml Eppendorf tubes and the nitrate was reduced to nitrite with 0.5 units of nitrate reductase (Boehringer Mannheim) in the presence of 50 µM NADPH and 5 µM FAD (6, 16). After oxidation of the NADPH excess (which interferes with the chemical determination of nitrite) with 0.2 mM pyruvate and 1 µg of lactate dehydrogenase, nitrite was determined with Griess reagent (16) by adding 1 mM sulfanilic acid and 100 mM HCl (final concentration). After incubation for 5 min the tubes were centrifuged, and 200 µl of supernatant were transferred to a 96-well microplate. After a first reading of the absorbance at 595 nm, 50 µl of naphthylenediamine (1 mM in the assay) were added. The reaction was completed after 15 min of incubation, and the absorbance at 595 nm was compared with a standard of NaNO2.

RNA Extraction and Analysis

Total RNA (3-4 × 106 cells) was extracted following the guanidinium thiocyanate method (26). After electrophoresis in a 0.9% agarose gel containing 2% formaldehyde the RNA was transferred to a Nytran membrane (NY 13-N; Schleicher & Schuell) with 10 × SSC (1.5 M NaCl, 0.3 M sodium citrate, pH 7.4). The membrane was prehybridized and the levels of iNOS or Ikappa B-alpha mRNA were determined using EcoRI-HindII or HindII-NotI fragments from the iNOS and Ikappa B-alpha cDNA, respectively (24, 27), labeled with [alpha -32P]dCTP using the random primed labeling kit (Boehringer Mannheim). The membranes were washed with 0.1 × SSC and 0.1% SDS at room temperature for 10 min and twice at 50 °C for 30 min, followed by exposure to x-ray film (Hyperfilm, Amersham Corp.). Different exposition times of the x-ray films were used to ensure that bands were not saturated. Quantification of the films was performed by laser densitometry (Molecular Dynamics) using the hybridization with a ribosomal 18 S probe as an internal standard.

Preparation of Cytosolic and Nuclear Extracts

A modified procedure based on the method of Schreiber et al. was used (28). The cell layers (3 × 106) were washed twice with ice-cold PBS, and the hepatocytes were collected in PBS by centrifugation at 50 × g for 5 min. The cell pellets were homogenized with 0.4 ml of buffer A (10 mM Hepes, pH 7.9, 1 mM EDTA, 1 mM EGTA, 10 mM KCl, 1 mM dithiothreitol, 0.5 mM phenylmethanesulfonyl fluoride, 2 µg/ml aprotinin, 10 µg/ml leupeptin, 2 µg/ml 1-chloro-3-tosylamido-7-amino-2-heptanone, 5 mM NaF, 1 mM NaVO4, 10 mM Na2MO4). After 10 min at 4 °C Nonidet P-40 was added to reach a 0.5% concentration. The tubes were gently vortexed for 15 s, and nuclei were sedimented by centrifugation at 8000 × g for 15 s. The supernatant was aliquoted and stored at -80 °C (cytosolic extract), and their pellet was resuspended in 100 µl of buffer A supplemented with 20% glycerol and 0.4 M KCl. Incubation was continued for 30 min at 4 °C with gentle vortexing. Nuclear proteins were extracted by centrifugation at 13,000 × g for 15 min and aliquots of the supernatant were stored at -80 °C. Proteins were measured using the Bio-Rad protein reagent following the recommendations of the supplier. All steps of cell fractionation were carried out at 4 °C.

EMSAs

The following synthetic oligonucleotides were prepared using an oligonucleotide synthesizer (Pharmacia Biotech Inc.) as follows: NF-kappa Bp (corresponding to proximal kappa B motif (nucleotides -92 to -65) of iNOS promoter (8, 9)), 5'-tcgaCCAACTGGGGACTCTCCCTTTGGGAACA-3' and 3'-GGTTGACCCCTGAGAGGGAAACCCTTGTagct-5'; NF-kappa Bd (corresponding to the distal kappa B motif (nucleotides -978 to -952) of this promoter), 5'-tcgaTGCTAGGGGGATTTTCCCTCTCTCTGT-3' and 3'-ACGATCCCCCTAAAAGGGAGAGAGACAagct-5'; GAS (corresponding to the Ly-6E promoter GAS site (29)), 5'-catgTTATGCATATTCCTGTAAGTG-3' and 3'-AATACGTATAAGGACATTCACcgtac-5'; SIE (corresponding to the high affinity SIE m67 site (29), 5'-gtcGACAGTTCCCGTCAATC-3' and 3'-GTCAAGGGCAGTTAGcagct-5'; AP-1 (consensus) (corresponding to the AP-1 motif of the albumin promoter (30)), 5'-tcgaTTCCAAAGAGTCATCAG-3' and 3'-AAGGTTTCTCAGTAGTCagct-5'.

The oligonucleotides were annealed after incubation for 5 min at 85 °C in 10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 10 mM MgCl2, and 1 mM dithiothreitol. Aliquots of 50 ng of these annealed oligonucleotides were end-labeled with the Klenow enzyme fragment in the presence of 50 µCi of [alpha -32P]dCTP and the other unlabeled dNTPs in a final volume of 50 µl. The oligonucleotides were precipitated in ethanol, extracted with phenol/chloroform to remove the unincorporated nucleotides, and 5 × 104 dpm of the DNA probe were used for each binding assay of nuclear extracts as follows: 5 µg of protein extract were incubated for 30 min at 4 °C with the DNA and 1 µg of poly(dI·dC)/ml, 5% glycerol, 1 mM EDTA, 100 mM KCl, 5 mM MgCl2, 1 mM dithiothreitol, 10 mM Tris-HCl, pH 7.8, in a final volume of 20 µl. The incubation mixture was applied to a 6% polyacrylamide gel which had been previously electrophoresed for 30 min at 100 V. Gels were run at 0.8 V/cm2 in 45 mM Tris-borate, followed by transfer to 3MM Whatman paper, drying under vacuum at 80 °C, and exposure at -80 °C to an x-ray film (Hyperfilm, Amersham) using an intensifying screen. Analysis of competition with unlabeled oligonucleotides was performed using a 20-fold excess of double stranded DNA in the binding reaction and adding the nuclear extracts as the last step in the binding assay. Supershift assays were carried out after addition of the antibody (0.5 µg) to the binding reaction and incubation for 1 h at 4 °C (22, 28).

Western Blot Analysis

Cytosolic and nuclear extracts were obtained as described previously for the EMSAs. After determining the protein content, samples were boiled in 250 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, and 2% beta -mercaptoethanol. Proteins (30 µg and 10 µg/lane for cytosolic and nuclear extracts, respectively) were size-separated in 10% SDS-polyacrylamide gel electrophoresis. The gels were processed as recommended by the supplier of the antibodies, anti-iNOS from Transduction Laboratories, and anti-Ikappa B-alpha , anti-Ikappa B-beta , anti-p52 (murine) from Santa Cruz Laboratories. Anti-p50 (human), anti-p65 (human), and anti-c-Rel (human) were a generous gift from Dr. N. R. Rice (31). After blotting onto a polyvinylidene fluorescein membrane (Millipore), proteins were revealed following the ECL technique (Amersham).


RESULTS

LPS, TPP, and PDBu Activate Hepatocytes Transfected with an Heterologous iNOS Promoter

Incubation of primary cultures of hepatocytes with LPS, TPP, and PDBu was found to promote iNOS expression and NO synthesis when assayed at 6 and 18 h after incubation with these factors (Fig. 1, A and B). Absence of iNOS mRNA levels and NO synthesis resulted when the hepatocytes were incubated with alpha -phorbol 12,13-didecanoate, an inactive phorbol ester (data not shown). To investigate whether the iNOS expression elicited by TPP and PDBu is mediated by the regulatory elements identified in the murine iNOS promoter, hepatocyte suspensions were transfected by electroporation with a plasmid (p1iNOS-CAT) containing a 1.8-kilobase fragment of the iNOS promoter region linked to a CAT gene, and CAT activity was measured after treatment with LPS, TPP, or PDBu. As Fig. 2A shows, hepatocytes transfected with this promoter construct exhibited a significant capacity to express CAT activity in response to these stimuli (7.2- and 14-fold increase in cells treated with PDBu and TPP or with LPS, respectively). Stimulation of hepatocytes transfected with a kSV2CAT vector with PDBu, TPP, or LPS did not affect CAT activity (Fig. 2B), suggesting a specificity in the response of the iNOS promoter to these factors. The release of NO and the expression of CAT activity by rat hepatocytes transfected with p1iNOS-CAT and stimulated with LPS, TPP, and PDBu suggest that the organization of the analyzed region of the iNOS promoter in murine and rat cells might be equivalent and therefore makes it possible to investigate the mechanism by which iNOS is induced by LPS, TPP, and PDBu on the basis of the known structure of the murine promoter.


Fig. 1. iNOS mRNA levels and NO synthesis in cultured hepatocytes stimulated with LPS, TPP, and PDBu. Hepatocytes (3 × 106 cells) were cultured in the presence of 1 µg/ml LPS, 5 µg/ml TPP, or 40 nM PDBu, and samples were collected at 6 (open bars) h and 18 h (hatched bars) to determine the NOx- released to the culture medium (A) and the mRNA levels of iNOS (B), respectively. The densitometric analysis of iNOS mRNA content was calculated after normalization of the 18 S ribosomal RNA content (B). Results show the mean ± S.E. of three experiments. *, p < 0.005 versus the control condition.
[View Larger Version of this Image (32K GIF file)]



Fig. 2. CAT activity is expressed in hepatocytes transfected with p1iNOS-CAT and stimulated with PDBu, TPP, and LPS. Hepatocytes were transfected by electroporation with 10 µg of plasmid and after seeding and stimulation with either 40 nM PDBu, 5 µg/ml TPP, or 1 µg/ml LPS CAT activity was determined after 24 h of culture. The amount of acetylated chloramphenicol was determined by counting the radioactivity of the corresponding spots, and CAT activity was expressed as the percentage of the activity of cells transfected with kSV2CAT plasmid (A). The effect of PDBu, TPP, and LPS on the activity of a control promoter construct (kSV2CAT) is shown (B). Results show the mean ± S.E. of three experiments. *, p < 0.01 versus nonstimulated cells transfected with p1iNOS-CAT.
[View Larger Version of this Image (31K GIF file)]


Characterization of Transcriptional Activation by Electrophoretic Mobility Shift Assays

The 1.8-kilobase murine iNOS promoter region contains at least 24 consensus sequences for the binding of transcriptional factors, and some of them have an important role in the control of iNOS expression (8, 9, 10, 11, 12). We have investigated whether the sequences corresponding to the distal and proximal kappa B motifs of the iNOS promoter, as well as GAS, SIE, and AP-1 motifs, bind nuclear factors in response to hepatocyte activation by LPS, TPP, and PDBu. As Fig. 3A shows, when the proximal NF-kappa B sequence was used for EMSA, an enhanced binding of nuclear proteins was observed in hepatocytes at 1 h after stimulation. In samples assayed at 6 h, the band corresponding to the b complex (p50/p65, see below) was significantly lower in hepatocytes incubated with PDBu but not when they were treated with LPS or TPP. Similar results were obtained when the distal kappa B sequence was assayed. The nature of the proteins that bind to the kappa B sequence were characterized using supershift assays. As Fig. 3B shows, the protein complexes retained in hepatocytes stimulated with 5 µg/ml TPP for 1 h corresponded to p50/p50 dimers (band a) and p50/p65 heterodimers (band b), respectively. Treatment of the nuclear extracts with anti-p52 or anti-c-Rel antibodies did not modify the pattern of bands, indicating the absence of the corresponding NF-kappa B/c-Rel proteins in the nuclei of control or stimulated hepatocytes. Identical supershift results were obtained using the distal kappa B sequence or when nuclear extracts where prepared from cells treated for 1 h with LPS or PDBu. In addition to kappa B, binding to AP-1, GAS, and SIE sequences reflected a similar pattern of engagement of these response elements (1 h after activation) in the mechanism of action of LPS, TPP, and PDBu (Fig. 4).


Fig. 3. EMSA of kappa B motifs using nuclear extracts from activated hepatocytes. Nuclear extracts were prepared from hepatocytes (3 × 106 cells) incubated for 1 or 6 h with 1 µg/ml LPS, 5 µg/ml TPP, or 40 nM PDBu. EMSAs were carried out using the labeled (5 × 104 dpm) kappa Bp sequence of the iNOS promoter as a probe. Controls to ensure the specificity of the interaction were performed using a 50-fold excess of the unlabeled probe to displace the binding (A). To analyze the proteins involved in the binding to the kappa Bp sequence, supershift assays were carried out using 1 µg of the indicated antibodies. Competition assays (50-fold excess of unlabeled oligonucleotide) and an unrelated competitor oligonucleotide (other motifs) were used to ensure band specificity. Similar results were obtained in hepatocytes stimulated with PDBu or LPS (B). The results show one representative experiment of four.
[View Larger Version of this Image (54K GIF file)]



Fig. 4. Binding of nuclear proteins to GAS, SIE, and AP-1 motifs. Nuclear extracts were prepared and assayed as described in Fig. 3. The oligonucleotide sequences were incubated with samples of 5 µg of nuclear proteins from cells treated for 1 h with 1 µg/ml LPS, 5 µg/ml TPP, or 40 nM PDBu. A 50-fold excess of unlabeled oligonucleotide completely displaced the binding in all cases. Results show one representative experiment of four.
[View Larger Version of this Image (73K GIF file)]


To ensure that the nuclear factors that bind kappa B and AP-1 sequences in EMSA operate effectively in intact cells and were not the result of nonspecific binding or cytosolic contamination of the nuclear extracts, hepatocytes were transfected with plasmids harboring a tandem of three kappa B ((kappa B)3ConACAT vector) or two AP-1 motifs ((AP-1)2ConACAT vector) linked to a minimal promoter (corresponding to the conalbumin A gene). As Fig. 5, A and B show, CAT activity increased at least 6-fold upon stimulation with PDBu, TPP, or LPS of hepatocytes transfected with (kappa B)3ConACAT or (AP-1)2ConACAT vectors. Transfection with a ConACAT plasmid failed to respond to these stimuli (data not shown).


Fig. 5. Transfection of hepatocytes with (kappa B)3ConACAT or (AP-1)2ConACAT plasmids resulted in increased CAT activity upon stimulation with PDBu, TPP, and LPS. Hepatocytes were transfected with 10 µg of (kappa B)3ConACAT (upper panel) or (AP-1)2ConACAT plasmids (lower panel), and after seeding and stimulation with 40 nM PDBu, 5 µg/ml TPP, or 1 µg/ml LPS CAT activity was determined after 24 h of incubation. CAT activity was expressed as a percentage of the activity of cells transfected with a kSV2CAT plasmid. Results correspond to the mean ± S.E. of three experiments. P values <0.01 were obtained for stimulated versus control cells.
[View Larger Version of this Image (49K GIF file)]


Characterization of the Proteins Involved in NF-kappa B Activation

In order to characterize the proteins involved in the activation of kappa B motifs, the amount of p50 and p65 in the cytosolic and nuclear extracts from activated hepatocytes was assessed by Western blot. As Fig. 6 shows, p65 was translocated from the cytosol to the nuclear compartment in stimulated cells. The amount of p65 present in nuclear extracts of untreated cells was negligible, confirming the results observed by EMSA (Fig. 3). Regarding p50, the protein was immunodetected in the nuclear extracts of control cells and the levels increased upon translocation from the cytosol to the nucleus after cell stimulation with either LPS, TPP, or PDBu.


Fig. 6. Western blot analysis of p50 and p65 in extracts from stimulated hepatocytes. Cytosolic (30 µg of protein/lane) and nuclear (10 µg of protein/lane) extracts were prepared from cells incubated with 1 µg/ml LPS, 5 µg/ml TPP, or 40 nM PDBu for the indicated period of time. Proteins were size-fractionated in a 10% SDS-polyacrylamide gel and the content of p65 and p50 was measured by Western blot. The densitometric analysis of the bands is given in the right panel. Open bars, cytosol; solid bars, nucleus. Results show the mean ± S.E. of three blots.
[View Larger Version of this Image (34K GIF file)]


Dissociation and degradation of the Ikappa B moieties of the cytosolic NF-kappa B complexes is an important mechanism for the control of the translocation to the nucleus of members of the Rel family (32). Since the amount of NF-kappa B/Rel proteins that become free to access to the nucleus is supposed to be proportional to the degradation of Ikappa B, we measured the Ikappa B-alpha and Ikappa B-beta protein levels in the cytosol by Western blot. As Fig. 7 shows, the levels of Ikappa B-alpha 1 h after stimulation of hepatocytes with LPS, TPP, or PDBu decreased by 64, 73, or 42%, respectively. However, the levels of Ikappa B-alpha at 6 h fully recovered in the cytosol independently of the treatment of the cells. Regarding Ikappa B-beta , this protein only decreased in cells treated with LPS for 1 h, and control levels were restored 6 h after stimulation. At the mRNA level, an important up-regulation of Ikappa B-alpha was observed in cells stimulated for 6 h with LPS and TPP and to a lesser extent in cells treated with PDBu (Fig. 8). In hepatocytes stimulated for 18 h with LPS an important increase of the Ikappa B-alpha mRNA levels was still evident.


Fig. 7. Western blot analysis of Ikappa B-alpha and Ikappa B-beta . Cytosolic extracts (30 µg of protein/lane) from cells treated for 1 or 6 h with 1 µg/ml LPS, 5 µg/ml TPP, or 40 nM PDBu were analyzed by Western blot using murine anti-Ikappa B-alpha or Ikappa B-beta antibodies. Results show the means ± S.E. of three blots. * and ** are given for p < 0.05 and p < 0.001 of the differences between control and stimulated cells at each sampling time.
[View Larger Version of this Image (51K GIF file)]



Fig. 8. Up-regulation of Ikappa B-alpha mRNA in stimulated hepatocytes. Cells were incubated for 6 (open bars) or 18 h (hatched bars) with LPS (1 µg/ml), TPP (5 µg/ml), or PDBu (40 nM) and the mRNA of Ikappa B-alpha was determined by Northern blot. The right panel shows the relative intensity of the bands after normalization for the 18 S ribosomal RNA content. Results show the mean ± S.E. of three experiments. *, p < 0.05 for the differences between stimulated cells and controls.
[View Larger Version of this Image (29K GIF file)]


Role of NF-kappa B Activation on iNOS Expression

To investigate further the importance of nuclear binding of proteins from the Rel family to the kappa B sites, experiments were undertaken in which cells were treated for 1 h prior to exposure to LPS, TPP, or PDBu with pyrrolidine dithiocarbamate (25 µM), an inhibitor of Ikappa B degradation. As Table I shows, pyrrolidine dithiocarbamate abrogated the NO synthesis elicited by hepatocytes incubated with LPS, TPP, or PDBu to the same extent. Under these conditions, an important reduction in the nuclear content of p50/p65 complexes was observed, reflecting the fact that NF-kappa B activation is required for iNOS expression in response to either LPS, TPP, or PDBu in hepatocytes.

Table I.

Effect of PDTC on NO synthesis and p50/p65 nuclear complexes in activated hepatocytes

Cells (6 × 106) were treated with 25 µM PDTC prior to stimulation with 1 µg/ml LPS, 5 µg/ml TPP, or 40 nM PDBu and incubated for 6 h. NO synthesis was achieved using Griess reagent. The presence of p50/p60 dimers in the nuclear extracts was determined by EMSA using the proximal NF-kappa B oligonucleotide as target. The nature of the proteins present in the retarded bands was confirmed by supershift analysis with anti-p50 and anti-p65 antibodies (human origin). Quantitation of the amount of p50/p65 complexes was done by densitometric analysis of the corresponding unsaturated films of EMSA. Results show the mean ± S.E. of three experiments. PDTC, pyrrolidine dithiocarbamate.
Stimulus NOx-
p50/p65 intensity
Alone +PDTC Alone +PDTC

nmol/mg protein arbitrary units
None 2.2  ± 0.3 0.5 3.1  ± 0.2 <1
LPS, 1 µg/ml 17  ± 3 2  ± 0.3 56  ± 6 9  ± 2
TPP, 5 µg/ml 15  ± 3 3  ± 0.1 45  ± 4 11  ± 3
PDBu, 40 nM 14  ± 2 2  ± 0.2 39  ± 5 8  ± 2

The relative contribution of each kappa B site to the activity of the iNOS promoter was analyzed using constructs in which the proximal and/or distal sequences were mutated to abolish the binding of NF-kappa B/Rel proteins (substitution of the GGG motif by the CCG sequence). As Fig. 9 shows, mutants of the proximal site (pNOS-kappa Bp- vector) still retained 27-35% of the original promoter activity, whereas mutation of the distal kappa B site (pNOS-kappa Bd- vector) resulted in 82-84% inhibition of the promoter activity, regardless of treatment of hepatocytes with LPS, TPP, or PDBu. As predicted on the basis of the data reported in Table I, simultaneous mutation of both kappa B sites (pNOS-kappa Bp-,d- vector) eliminated the promoter activity.

The relative contribution of the two AP-1 binding sites to the promoter activity was investigated using deletional mutants. As Fig. 9 also shows, promoter activity of the vector p1iNOS(Delta 1), which contains both the distal and proximal AP-1 sites, was roughly similar to the activity of the pNOS-kappa B vector, which lacks the distal AP-1 site, independently of the stimulation with bacterial products or phorbol esters. The same behavior was observed when the promoter activity of p1iNOS(Delta 2), which contains the proximal AP-1 and kappa B sites, was compared with the activity of the vector p1iNOS(Delta 3), which lacks the proximal AP-1 site (Fig. 9). These results agree with the data reported by other authors using different approaches and suggest that the activity of the promoter is totally independent of AP-1 activation.


DISCUSSION

The expression of iNOS in response to LPS and TPP is well established among different cell types; however, the ability of phorbol esters to induce iNOS seems to be restricted to some cell types such as hepatocytes, peritoneal rat macrophages, and astrocytes (5, 6, 33, 34). For this reason, primary cultures of rat hepatocytes were used to investigate the transcriptional control mediating iNOS expression in response to bacterial products and phorbol esters.

The promoter region of the rat iNOS gene is still unknown, but it is likely to be closely related to the cloned murine sequence in view of the similarities in the transactivation mechanism of iNOS (8, 9, 25, 33). We first confirmed that rat hepatocytes transfected with a plasmid harboring an heterologous murine iNOS promoter displayed a functional behavior that was equivalent to the response described in murine cells (8, 9) and paralleled the release of NO by the endogenous enzyme, therefore suggesting that, as a first approach, this murine promoter region contains regulatory sequences activated upon treatment of rat hepatocytes with LPS, TPP, or phorbol esters.

The involvement of NF-kappa B activation in the iNOS expression mechanism elicited by proinflammatory cytokines and LPS has been widely recognized as an absolute requirement (10, 11), and in this regard, incubation of hepatocytes with pyrrolidine dithiocarbamate, an inhibitor of Ikappa B degradation (35), blocked the NO synthesis mediated in response to LPS, TPP, and phorbol esters. These results were confirmed using promoter mutants in which both kappa B sites have been suppressed. On analysis, the distal kappa B site contributed more than the proximal to the activity of the promoter, in agreement with the results reported by Spink et al. (25) in rat vascular smooth muscle cells. In hepatocytes transfected with plasmids containing kappa B sequences we have confirmed the involvement of NF-kappa B upon stimulation with both TPP and PDBu, in addition to the expected response to LPS. The characterization of the proteins involved in the formation of the NF-kappa B complexes (36) in activated hepatocytes revealed the presence of p50/p65 heterodimers as detected by supershift assays and by Western blotting. The translocation of NF-kappa B proteins from the cytosol to the nucleus is largely dependent on the phosphorylation and degradation of the Ikappa B subunits present in the cytosolic complexes (36, 37, 38). In hepatocytes, treatment with LPS, TPP, or PDBu decreased the Ikappa B-alpha levels at 1 h, and only LPS was able to decrease the amount of Ikappa B-beta , which is in agreement with previous results (38). It is possible that the regulation of binding to kappa B motifs in activated hepatocytes is even more complex, because NO seems to be an important modulator of Ikappa B-alpha function (39). However, NO has no effect on Ikappa B-beta levels or over other transcription factors such as AP-1 or GATA (39). The importance of the role of Ikappa B-alpha in the regulation of NF-kappa B functioning is underlined by the observation that the transrepression of NF-kappa B by glucocorticoids is due to the control exerted by these hormones on Ikappa B-alpha levels (40).

The 1.7-kilobase murine iNOS promoter region that has been characterized contains two AP-1-related binding sequences (8, 9), which prompted us to investigate the effect of this transcription factor upon hepatocyte stimulation. Fos and Jun form part of the dimeric complex recognized as AP-1, and this transcription factor participates in the regulation of the basal or the inducible activity of several genes (41). As expected from previous work (41, 42, 43), PDBu and LPS stimulated the binding of proteins to AP-1 consensus sequences at the time that induced CAT activity in hepatocytes transfected with a (AP-1)2ConA-CAT plasmid. The ability of TPP to activate AP-1 was previously unrecognized. However, deletion of the AP-1 binding sites in the iNOS promoter did not affect the reporter activity in hepatocytes stimulated with LPS, TPP, or PDBu. These results confirm the low contribution of the AP-1 sites to the activity of the iNOS promoter in macrophages stimulated with cytokines (8, 9). Current view about transcriptional activation through the AP-1 complex stresses the importance of the phosphorylation at distinct residues of c-Jun as a critical requirement for the stability and transcriptional activity of AP-1 (41, 43, 44). Therefore, since several kinases can independently regulate AP-1 activity, the mechanisms that maintain a functionally active AP-1 complex in hepatocytes stimulated with LPS, TPP, or PDBu might be different.

IFN-gamma has proved to be an important cytokine for iNOS induction, synergistically acting with LPS and tumor necrosis factor-alpha or with phorbol esters in a more exclusive fashion (1, 11, 12, 34, 45, 46). These effects of IFN-gamma on iNOS transcription have been attributed to the presence in the murine promoter region of this gene of a sequence for binding of interferon regulatory factor-1 (IRF-1), and this motif acts in combination with the distal NF-kappa B site, giving rise to IFN-gamma -dependent potentiation when macrophages are activated with suboptimal doses of LPS (8, 9, 10, 11). In addition to this, two important targets of IFN-gamma action are the GAS and SIE motifs to which STAT proteins bind (29). GAS and SIE sequences are activated not only by IFN-gamma but also by other cytokines such as epidermal growth factor, platelet-derived growth factor, and interleukin-6, the latter being an important cytokine that participates in the hepatic acute phase response (14, 47, 48). Moreover, a GAS site has been identified in the promoter region of the IRF-1 gene, suggesting a feedback up-regulation of this important transcription factor for iNOS expression (49). Using the GAS site of the Ly-6E gene promoter (29), we observed in EMSA the presence of a specific band 1 h after stimulation of hepatocytes with LPS, TPP, or PDBu. Although the nature of the proteins that participate in the shift have not yet been identified, they are reminiscent of those detected in FS2 cells stimulated with IFN-gamma (29). Regarding the SIE sequence, we detected one "constitutive" band in control cells (presumably STAT1 homodimers), but upon cell stimulation two additional bands were detected (possibly STAT1·STAT3 heterodimers and STAT3 homodimers). These results suggest that in hepatocytes stimulated with LPS, TPP, or PDBu, common transcription factors that bind to the GAS and SIE sequences are translocated to the nucleus.

The results reported extend previous work from other groups on the identification of the pathways involved in the transcriptional control of iNOS, taking advantage of a system where the enzyme can be induced in response to different stimuli such as LPS, TPP, and phorbol esters. Moreover, it cannot be ruled out that some of the agents used (phorbol esters or bacterial products) might induce the release to the medium or the synthesis of other factors (for example, tumor necrosis factor-alpha or interleukin-6 by the minimal presence of Kupffer cells in the hepatocyte culture) that could be the final mediators of the response in a way similar to that described for the control of T cell activation via interleukin-2 receptor, in which secreted lymphokines play a prominent role in the time course of T cell triggering (50, 51).

Finally, throughout this work we have observed that the transcriptional control of iNOS expression in response to these three unrelated molecules, LPS, TPP, and PDBu, is driven by the use of common NF-kappa B/Rel transcription factors. The knowledge of the transcriptional mechanisms that control iNOS expression in the hepatocyte may contribute to a better understanding of the role of NO in hepatic pathophysiology (47).


FOOTNOTES

*   This work was supported by Grant PM95-007 from the Comisión Interministerial de Ciencia y Tecnología, Spain. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed. E-mail: boscal{at}eucmax.sim.ucm.es.
1   The abbreviations used are: iNOS, type II nitric oxide synthase; LPS, lipopolysaccharide; TPP, S-[2,3-bis(palmitoyloxy)-(2-R,S)-propyl]-N-palmitoyl-(R)-Cys-Ser-Lys4; PDBu, phorbol 12,13-dibutyrate; IFN-gamma , interferon-gamma ; EMSA, electrophoretic mobility shift assay; CAT, chloramphenicol acetyltransferase; GAS, gamma -activated site; PBS, phosphate-buffered saline.

Acknowledgments

We thank O. G. Bodelón for technical support, Drs. S. Lamas and M. Fresno for the critical reading of the manuscript, D. A. Gilson for help in the preparation of the manuscript, Dr. Q.-w. Xie and C. Nathan for the generous gift of the inducible NOS cDNA probe, and Dr. T. J. Evans for the gift of the mutated kappa B sequences of the iNOS promoter.


REFERENCES

  1. Nathan, C. (1992) FASEB J. 6, 3051-3064 [Medline] [Abstract]
  2. Moncada, S., Palmer, R. M. J., and Higgs, E. A. (1991) Pharmacol. Rev. 43, 109-142 [Medline] [Medline] [Order article via Infotrieve]
  3. Marletta, M. A. (1993) J. Biol. Chem. 268, 12231-12234 [Medline] [Free Full Text]
  4. Nathan, C., and Xie, Q.-w. (1994) Cell 78, 915-918 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  5. Hortelano, S., Genaro, A. M., and Boscá, L. (1992) J. Biol. Chem. 267, 24937-24940 [Medline] [Abstract/Free Full Text]
  6. Terenzi, F., Díaz-Guerra, M. J. M., Casado, M., Hortelano, S., Leoni, S., and Boscá, L. (1995) J. Biol. Chem. 270, 6017-6021 [JBC][Medline] [Abstract/Free Full Text]
  7. Chu, S. C., Wu, H.-P., Banks, T. C., Eissa, N. T., and Moss, J. (1995) J. Biol. Chem. 270, 10625-10630 [JBC][Medline] [Abstract/Free Full Text]
  8. Xie, Q.-w., Whisnant, R., and Nathan, C. (1993) J. Exp. Med. 177, 1779-1784 [Medline] [Abstract/Free Full Text]
  9. Lowenstein, C. J., Alley, E. W., Raval, P., Snowman, A. M., Snyder, S. H., Russell, S. W., and Murphy, W. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9730-9734 [Medline] [Abstract/Free Full Text]
  10. Xie, Q., Kashiwabara, Y., and Nathan, C. (1994) J. Biol. Chem. 269, 4705-4708 [Medline] [Abstract/Free Full Text]
  11. Nathan, C., and Xie, Q. (1994) J. Biol. Chem. 269, 13725-13728 [Medline] [Free Full Text]
  12. Martin, E., Nathan, C., and Xie, Q-w. (1994) J. Exp. Med. 180, 977-984 [Medline] [Abstract/Free Full Text]
  13. Weisz, A., Oguchi, S., Cicatiello, L., and Esumi, H. (1994) J. Biol. Chem. 269, 8324-8333 [Medline] [Abstract/Free Full Text]
  14. Geller, D. A., Nussler, A. K., Di Silvio, M., Lowenstein, C. J., Shapiro, R. A., Wang, S. C., Simmons, R. L., and Billiar, T. R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 522-526 [Medline] [Abstract/Free Full Text]
  15. Bomzon, A., and Blendis, L. M. (1994) Hepatology 20, 1343-1350 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  16. Hortelano, S., Dewez, B., Genaro, A. M., Díaz-Guerra, M. J. M., and Boscá, L. (1995) Hepatology 21, 776-786 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  17. Fausto, N. (1990) in Hepatology: A Textbook of Liver Disease (Zakim, D., and Boyer, T. D., eds), pp. 49-62, W. B. Saunders, Philadelphia
  18. Delude, R. L., Fenton, M. J., Savedra, R., Jr., Perera, P.-Y., Vogel, S. N., Thieringer, R., and Golenbock, D. T. (1994) J. Biol. Chem. 269, 22253-22260 [Medline] [Abstract/Free Full Text]
  19. Bessler, W. G., and Jung, G. (1992) Res. Immunol. 143, 548-553 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  20. Nishizuka, Y. (1988) Nature 334, 661-665 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  21. Hortelano, S., Genaro, A. M., and Boscá, L. (1993) FEBS Lett. 320, 135-139 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  22. Bergot, M-O., Díaz-Guerra, M. J. M., Puzenat, N., Raymondjean, M., and Kahn, A. (1992) Nucleic Acids Res. 20, 1871-1878 [Medline] [Abstract/Free Full Text]
  23. Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Mol. Cell. Biol. 2, 1044-1051 [Medline] [Abstract/Free Full Text]
  24. Lozano, J., Berra, E., Municio, M. M., Díaz-Meco, M. T., Dominguez, I., Sanz, L., and Moscat, J. (1994) J. Biol. Chem. 269, 19200-19202 [Medline] [Abstract/Free Full Text]
  25. Spink, J., Cohen, J., and Evans, T. J. (1995) J. Biol. Chem. 270, 29541-29547 [JBC][Medline] [Abstract/Free Full Text]
  26. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159 [Medline] [Medline] [Order article via Infotrieve]
  27. Xie, Q.-w., Cho, H. J., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T. D., Ding, A., Troso, T., and Nathan, C. (1992) Science 256, 225-228 [Medline] [Abstract/Free Full Text]
  28. Schreiber, E., Matthias, P., Müller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17, 6419-6424 [Medline] [Free Full Text]
  29. Sadowski, H. B., Shuai, K., Darnell, J. E., Jr., and Gilman, M. Z. (1993) Science 261, 1739-1744 [Medline] [Abstract/Free Full Text]
  30. Baeuerle, P. A., and Henkel, T. (1994) Annu. Rev. Immunol. 12, 141-179 [Medline] [Medline] [Order article via Infotrieve]
  31. Ghosh, P., Tan, T.-H., Rice, N. R., Sica, A., and Young, H. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1696-1700 [Medline] [Abstract/Free Full Text]
  32. Lenardo, M. J., and Baltimore, D. (1989) Cell 58, 227-229 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  33. Nussler, A. K., DiSilvio, M., Liu, Z., Geller, D. A., Freeswick, P., Dorko, K., Bartoli, F., and Billiar, T. R. (1995) Hepatology 21, 1552-1560 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  34. Simmons, M. L., and Murphy, S. (1994) Glia 11, 227-234 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  35. Schreck, R., Meier, B., Männel, D. N., Dröge, W., and Baeuerle, P. A. (1992) J. Exp. Med. 175, 1181-1194 [Medline] [Abstract/Free Full Text]
  36. Thanos, D., and Maniatis, T. (1995) Cell 80, 529-532 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  37. DiDonato, J. A., Mercurio, F., and Karin, M. (1995) Mol. Cell. Biol. 15, 1302-1311 [Medline] [Abstract]
  38. Thomson, J. E., Philips, R. J., Erdjument-Bromage, H., Tempst, P., and Ghosh, S. (1995) Cell 80, 573-582 [CrossRef][Medline] [Order article via Infotrieve]
  39. Peng, H.-B., Libby, P., and Liao, J. K. (1995) J. Biol. Chem. 270, 14214-14219 [JBC][Medline] [Abstract/Free Full Text]
  40. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., and Karin, M. (1995) Science 270, 286-290 [Medline] [Abstract/Free Full Text]
  41. Angel, P., and Karin, M. (1991) Biochim. Biophys. Acta 1072, 129-157 [Medline] [Medline] [Order article via Infotrieve]
  42. König, G., Ponta, H., Rahmsdorf, H. J., and Herrlich, P. (1992) EMBO J. 11, 2241-2246 [Medline] [Order article via Infotrieve]
  43. Westwick, J. K., Weitzel, C., Minden, A., Karin, M., and Brenner, D. A. (1994) J. Biol. Chem. 269, 26396-26401 [Medline] [Abstract/Free Full Text]
  44. Cano, E., and Mahadevan, L. C. (1995) Trends Biochem. Sci. 20, 117-122 [Medline] [CrossRef][Medline] [Order article via Infotrieve]
  45. Jun, C. D., Choi, B. M., Kim, H. M., and Chung, H. T. (1995) J. Immunol. 154, 6541-6547 [Medline] [Abstract]
  46. Jun, C. D., Choi, B. M., Hoon, R., Um, J. Y., Kwak, H. J., Lee, B. S., Paik, S. G., Kim, H. M., and Chung, H. T. (1994) J. Immunol. 153, 3684-3690 [Medline] [Abstract]
  47. Harbrecht, B. G., Stadler, J., Demetris, A. J., Simmons, R. L., and Billiar, T. R. (1994) Am. J. Physiol. 266, G1004-G1010 [Medline]
  48. Haber, B. A., Mohn, K. L., Diamond, R. H., and Taub, R. (1993) J. Clin. Invest. 91, 1319-1326 [Medline]
  49. Zhang, X., Blenis, J., Li, H. C., Schindler, C., and Chen-Kiang, S. (1995) Science 267, 1990-1994 [Medline] [Abstract/Free Full Text]
  50. Pimentel-Muiños, F. X., Muñoz-Fernández, M. A., and Fresno, M. (1994) J. Immunol. 152, 5714-5722 [Medline] [Abstract]
  51. Pimentel-Muiños, F. X., Mazana, J., and Fresno, M. (1994) J. Biol. Chem. 269, 24424-24429 [Medline] [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
P. O. Hassa, S. S. Haenni, C. Buerki, N. I. Meier, W. S. Lane, H. Owen, M. Gersbach, R. Imhof, and M. O. Hottiger
Acetylation of Poly(ADP-ribose) Polymerase-1 by p300/CREB-binding Protein Regulates Coactivation of NF-{kappa}B-dependent Transcription
J. Biol. Chem., December 9, 2005; 280(49): 40450 - 40464.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Goren, J. Cuenca, P. Martin-Sanz, and L. Bosca
Attenuation of NF-{kappa}B signalling in rat cardiomyocytes at birth restricts the induction of inflammatory genes
Cardiovasc Res, November 1, 2004; 64(2): 289 - 297.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
X.-W. QU, H. WANG, I. G. DE PLAEN, R. A. ROZENFELD, and W. HSUEH
Neuronal nitric oxide synthase (NOS) regulates the expression of inducible NOS in rat small intestine via modulation of nuclear factor kappa B
FASEB J, February 1, 2001; 15(2): 439 - 446.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Castrillo, M. J. M. Díaz-Guerra, S. Hortelano, P. Martín-Sanz, and L. Boscá
Inhibition of Ikappa B Kinase and Ikappa B Phosphorylation by 15-Deoxy-Delta 12,14-Prostaglandin J2 in Activated Murine Macrophages
Mol. Cell. Biol., March 1, 2000; 20(5): 1692 - 1698.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
M. J. M. Diaz-Guerra, A. Castrillo, P. Martin-Sanz, and L. Bosca
Negative Regulation by Protein Tyrosine Phosphatase of IFN-{gamma}-Dependent Expression of Inducible Nitric Oxide Synthase
J. Immunol., June 1, 1999; 162(11): 6776 - 6783.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. J. M. Diaz-Guerra, A. Castrillo, P. Martin-Sanz, and L. Bosca
Negative Regulation by Phosphatidylinositol 3-Kinase of Inducible Nitric Oxide Synthase Expression in Macrophages
J. Immunol., May 15, 1999; 162(10): 6184 - 6190.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C.-C. Chen and J.-K. Wang
p38 but Not p44/42 Mitogen-Activated Protein Kinase Is Required for Nitric Oxide Synthase Induction Mediated by Lipopolysaccharide in RAW 264.7 Macrophages
Mol. Pharmacol., March 1, 1999; 55(3): 481 - 488.
[Abstract] [Full Text]


Home page
J. Cell Sci.Home page
N. Callejas, M Casado, L Bosca, and P Martin-Sanz
Requirement of nuclear factor kappaB for the constitutive expression of nitric oxide synthase-2 and cyclooxygenase-2 in rat trophoblasts
J. Cell Sci., January 9, 1999; 112(18): 3147 - 3155.
[Abstract] [PDF]


Home page
J. Immunol.Home page
E. D. Chan, B. W. Winston, S.-T. Uh, M. W. Wynes, D. M. Rose, and D. W. H. Riches
Evaluation of the Role of Mitogen-Activated Protein Kinases in the Expression of Inducible Nitric Oxide Synthase by IFN-{gamma} and TNF-{alpha} in Mouse Macrophages
J. Immunol., January 1, 1999; 162(1): 415 - 422.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C.-C. Chen, J.-K. Wang, and S.-B. Lin
Antisense Oligonucleotides Targeting Protein Kinase C-{alpha}, -{beta}I, or -{delta} But Not -{eta} Inhibit Lipopolysaccharide-Induced Nitric Oxide Synthase Expression in RAW 264.7 Macrophages: Involvement of a Nuclear Factor {kappa}B-Dependent Mechanism
J. Immunol., December 1, 1998; 161(11): 6206 - 6214.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. M. Rai, F. Y. J. Lee, A. Rosen, S. Q. Yang, H. Z. Lin, A. Koteish, F. Y. Liew, C. Zaragoza, C. Lowenstein, and A. M. Diehl
Impaired liver regeneration in inducible nitric oxide synthasedeficient mice
PNAS, November 10, 1998; 95(23): 13829 - 13834.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
B. E. Jones and M. J. Czaja
III. Intracellular signaling in response to toxic liver injury
Am J Physiol Gastrointest Liver Physiol, November 1, 1998; 275(5): G874 - G878.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-C. Chen, J.-K. Wang, W.-C. Chen, and S.-B. Lin
Protein Kinase C eta  Mediates Lipopolysaccharide-induced Nitric-oxide Synthase Expression in Primary Astrocytes
J. Biol. Chem., July 31, 1998; 273(31): 19424 - 19430.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Z. S. Han, H. Enslen, X. Hu, X. Meng, I-H. Wu, T. Barrett, R. J. Davis, and Y. T. Ip
A Conserved p38 Mitogen-Activated Protein Kinase Pathway Regulates Drosophila Immunity Gene Expression
Mol. Cell. Biol., June 1, 1998; 18(6): 3527 - 3539.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
W. Eberhardt, C. Pluss, R. Hummel, and J. Pfeilschifter
Molecular Mechanisms of Inducible Nitric Oxide Synthase Gene Expression by IL-1{beta} and cAMP in Rat Mesangial Cells
J. Immunol., May 15, 1998; 160(10): 4961 - 4969.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Lopez-Collazo, S. Hortelano, A. Rojas, and L. Bosca
Triggering of Peritoneal Macrophages with IFN-{alpha}/{beta} Attenuates the Expression of Inducible Nitric Oxide Synthase Through a Decrease in NF-{kappa}B Activation
J. Immunol., March 15, 1998; 160(6): 2889 - 2895.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Da Silva, B. Pierrat, J.-L. Mary, and W. Lesslauer
Blockade of p38 Mitogen-activated Protein Kinase Pathway Inhibits Inducible Nitric-oxide Synthase Expression in Mouse Astrocytes
J. Biol. Chem., November 7, 1997; 272(45): 28373 - 28380.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Velasco, M. J. M. Diaz-Guerra, P. Martin-Sanz, A. Alvarez, and L. Bosca
Rapid Up-regulation of Ikappa Bbeta and Abrogation of NF-kappa B Activity in Peritoneal Macrophages Stimulated with Lipopolysaccharide
J. Biol. Chem., September 12, 1997; 272(37): 23025 - 23030.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Castrillo, B. de las Heras, S. Hortelano, B. Rodriguez, A. Villar, and L. Bosca
Inhibition of the Nuclear Factor kappa B (NF-kappa B) Pathway by Tetracyclic Kaurene Diterpenes in Macrophages. SPECIFIC EFFECTS ON NF-kappa B-INDUCING KINASE ACTIVITY AND ON THE COORDINATE ACTIVATION OF ERK AND p38 MAPK
J. Biol. Chem., May 4, 2001; 276(19): 15854 - 15860.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Castrillo, M. Mojena, S. Hortelano, and L. Bosca
Peroxisome Proliferator-activated Receptor-gamma -independent Inhibition of Macrophage Activation by the Non-thiazolidinedione Agonist L-796,449. COMPARISON WITH THE EFFECTS OF 15-DEOXY-Delta 12,14-PROSTAGLANDIN J2
J. Biol. Chem., August 31, 2001; 276(36): 34082 - 34088.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Díaz-Guerra, M. J.M.
Right arrow Articles by Boscá, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Díaz-Guerra, M. J.M.
Right arrow Articles by Boscá, L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement